Dr. Cabilly is a highly regarded scientist, an investor and an experienced Board Member of several companies. He is currently a Board Member of Medasense Biometrics Ltd. He previously worked for several companies including as the Co-Founder and a Chief Scientist of Ethrog Biotechnology which was sold to Invitrogen.
Dr. Cabilly graduated from the Hebrew University (Ph.D., Immunology), and was a Post-Doctoral fellow at the City of Hope Research Institute heading a joint City of Hope/Genentech project where he developed a new technology for recombinant antibody production. This invention was patented in world patents “The old Cabilly” and “The New Cabilly patent”. Today there are already 20 drugs in the market based on this technology among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and more.
There is much more to this profile.
Log in or sign up for free to see the whole thing.
Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats